| Literature DB >> 27990305 |
Elizabeth O'Keefe1, Katherine E Schwetye2, John Nazarian3, Richard Perrin4, Robert E Schmidt4, Robert Bucelli5.
Abstract
A 66-year-old woman presented with progressive lancinating pain and sensory deficits attributable to a myelopathy of unclear etiology. Spinal cord magnetic resonance imaging showed a longitudinally extensive T2-hyperintense lesion of the dorsal columns. Comprehensive serum, urine, and cerebrospinal fluid analyses failed to identify an etiology. Empiric intravenous methylprednisolone and intravenous immunoglobulin were of no benefit and serial screens for an occult malignancy were negative. She developed dysesthesias and allodynia affecting her entire body and lost the use of her arms and legs due to severe sensory ataxia that was steadily progressive from onset. She opted against additional aggressive medical management of her condition and passed away on hospice eleven months after symptom onset. Autopsy revealed findings most consistent with polyphasic spinal cord ischemia affecting the dorsal and lateral white matter tracts and, to a lesser extent, adjacent gray matter. The underlying etiology for the progressive vasculopathy remains unknown. Spinal cord ischemia affecting the posterior spinal cord is rare and to our knowledge this case represents the only instance of a progressive spinal cord tractopathy attributable to chronic spinal cord ischemia.Entities:
Year: 2016 PMID: 27990305 PMCID: PMC5136626 DOI: 10.1155/2016/4125294
Source DB: PubMed Journal: Case Rep Neurol Med ISSN: 2090-6676
Figure 1Sagittal T2-weighted MR images through the cervical (a) and thoracic (b) spine demonstrate diffuse, hyperintense signal in the posterior columns, extending nearly the entire length of the spinal cord. An axial T2W image at T9-T10 (c) demonstrates the cross-sectional extent of the signal abnormality.
Relevant data.
|
| ||
| Vitamin B12 (211–911 pg/mL) | 524 pg/mL | |
| Methylmalonic acid (≤0.40 nmol/L) | 0.31 nmol/L | |
| Homocysteine (5–15 | 11.7 | |
| Vitamin E (5.5–17.0 mg/L) | 17.7 mg/L | |
| TSH (0.35–5.50 mcIU/mL) | 1.07 mcIUnits/mL | |
| Free T4 (0.9–1.8 ng/dL) | 1.12 ng/dL | |
|
| 4.4 mg/L | |
| ANA, ANCA, anti-dsDNA, ENA | Negative | |
| 24-hour urine heavy metals (mercury, lead, arsenic) | Negative | |
| 24-hour urine zinc (300–600 mcg/24 h) | 909 mcg/24 hr | |
| 24-hour urine copper (15–60 mcg/24 h) | 22 mcg/24 hr | |
| Serum paraneoplastic panel × 2 | 0.03 and 0.04 nmol/L | |
| Negative except for calcium channel ab N-type (<0.03) | ||
|
| ||
| CSF cytology | Negative | |
| Fine needle aspiration of right paratracheal lymph node | Negative | |
| Skin biopsy | Negative for lymphoma | |
| Quadriceps biopsy | Negative for lymphoma | |
|
| ||
| HIV | Negative | |
| HTLV-1 | Negative | |
| RPR | Negative | |
| Mycobacteria (AFB) culture and acid fast stain | Negative | |
| PPD | Negative | |
| Blood cultures | Negative | |
| Urine cultures | Negative | |
| Respiratory cultures from bronchoalveolar lavage | Negative | |
| CSF culture × 2 | Negative | |
| Fungal culture of blood | Negative | |
|
|
|
|
| Glucose | 113 mg/dL | 120 mg/dL |
| Protein (15–45 mg/dl) | 30 mg/dL | 41 mg/dL |
| Nucleated cells (cells/ | 0 | 0 |
| Red blood cells | 0 | 0 |
| CSF IgG index (≤0.85) | 0.6 | 0.62 |
| CSF specific oligoclonal bands | 0 | 0 |
| CSF paraneoplastic panel | Negative | |
| CSF cytology | ||
|
| ||
| Length-dependent sensorimotor axonal polyneuropathy with small sural sensory nerve action potential amplitudes and EMG evidence of subacute and chronic neurogenic changes limited to a distal leg muscle. | ||
TSH, thyroid stimulating hormone; HIV, human immunodeficiency virus; HTLV, human T-lymphotropic virus; RPR, rapid plasma reagin; ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; dsDNA, double-stranded DNA; ENA, extractable nuclear antigen.
Paraneoplastic panel: antistriated muscle; antiacetylcholine receptor (ganglionic neuronal); anti-voltage-gated calcium channel binding P/Q type; CRMP-5 IgG; antineuronal nuclear 1, 2, 3; Purkinje cell cytoplasmic types 1 and 2 and TR; amphiphysin, antiglial nuclear; antineuronal voltage-gated potassium channel; and anti-GAD65 antibodies. CSF panel tested with indirect immunofluorescence assay and serum panel tested with indirect immunofluorescence assay and radioimmunoassay (RIA) [12].
Figure 2Acute and subacute ischemic changes in the spinal cord. (a, b) Intermediate-power and high-power photomicrographs of dorsal columns in a section with neutrophilic infiltrates and reactive vessels (original magnifications, ×40 and ×400, resp.; H-E stain); (c) low-power photomicrograph of spinal cord stained with antibody against CD68 to demonstrate foamy macrophages and microglia, primarily within dorsal columns and lateral white matter tracts (original magnification, ×20; CD68 immunostain); (d) higher-power photomicrograph of the dorsal columns showing CD68-positive macrophages and microglia (original magnification, ×200; CD68 immunostain).
Figure 3Histologic sections of spinal cord demonstrate extensive white matter pathology. (a) Low-power photomicrograph of spinal cord with dorsal column and lateral white matter degeneration (original magnification, ×20; hematoxylin-eosin [H-E] stain); (b) low-power photomicrograph of spinal cord stained with Luxol fast blue-periodic acid Schiff (LFB-PAS) histochemistry to demonstrate loss of myelinated axons (original magnification, ×20; LFB-PAS stain).
Figure 4Spinal cord stained immunohistochemically with antibody to neurofilament (NF) demonstrates regional axonal loss; (a) low-power photomicrograph demonstrates areas of axonal loss most pronounced in the dorsal (upper boxed area) and lateral white matter tracts, in contrast to ventral spinal cord (lower boxed area) (original magnification, ×20; NF immunostain); (b, c) higher-power photomicrographs of boxed areas to demonstrate axonal loss in dorsal columns ((b) upper boxed area from (a)) with relative axonal preservation in ventral area ((c) lower boxed area from (a)) (original magnifications, ×200; NF immunostain).
Figure 5Gray matter damage. (a) Lower-power photomicrograph of gray matter adjacent to ventrolateral tracts (original magnification, ×40; H-E stain); (b) higher-power photomicrograph of adjacent gray matter with neuronal loss and gliosis (original magnification, ×400; H-E stain).